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What this paper adds? 
Status dystonicus remains a complex multisystem disorder and usually involves a multidisciplinary 
approach. 
Clonidine may provide a suitable alternative to benzodiazepines and opiate infusions in the 
management of childhood status dystonicus. 
Clonidine doses of 0.5-3mcg/kg/hour (range 0.1- 9mcg/kg/hour) may be necessary to safely manage 
acute severe dystonia and in our experience does not result in severe hypotension or respiratory 
depression 
Severe dystonia is effectively managed using the Dystonia Severity Assessment Plan (DSAP) scoring 
system which monitors worsening and improvement in dystonia based on meaningful function and 
comfort 
Clonidine helps to restore sleep in dystonic children which in turn is crucial for breaking the vicious 
cycle of continuous muscular contraction of dystonia 
Attention to the sleep patterns of children with dystonia and improving their often fragmented sleep 
forms the cornerstone of dystonia management 
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Abstract 
Objective 
Acute dystonia in children is distressing, painful and can progress to life-threatening status 
dystonicus. Typical management involves benzodiazepines which can result in respiratory depression 
requiring PICU admission. Clonidine is less respiratory-depressant, and by facilitating sleep, switches 
dystonia off. It can also be administered via enteral, continuous intravenous infusion, and transdermal 
slow release routes. We describe the dose range and safety profile of clonidine treatment in a case-
series of children with severe acute exacerbation of dystonia in a tertiary hospital setting.  
Methods  
The management of 5 children (3 female, age range 8-14 years) suffering from an acute exacerbation 
of secondary dystonia requiring hospital admission at the Evelina London Children’s Hospital was 
reviewed. The average and maximum dose of clonidine in mcg/kg/hr and routes of administration 
were recorded for each day of hospital admission. Co-administration of any other medical treatments 
for dystonia and their route of administration were also recorded. Cardiovascular and respiratory 
clinical status were measured by recording the daily mean and maximum Paediatric Early Warning 
Scores (PEWS).  
Results 
Clonidine was administered via enteral, intravenous, and transdermal routes at a median dose of 
2.5mcg/kg/hr (range 0.1 to 9 mcg/kg/hr). Administration of high dose clonidine was associated with 
decreased use of benzodiazepines, morphine, and propofol: avoiding invasive respiratory support for 
¾ cases during admission. Clonidine doses via all routes of administration did not correlate with 
poorer PEWS scores (p=0.839).Both high dose intravenous and transdermal clonidine where found to 
be effective.  
Conclusions: High dose clonidine administered via different routes can be used in the acute 
management of severe exacerbations of dystonia. Its use in our cohort was not associated with 
significant cardio-respiratory depression even at doses as high as 9 mcg/kg/hr.  
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Introduction 
Dystonia is characterised by involuntary sustained or intermittent muscle contractions that cause 
abnormal, often repetitive movements, postures or both.
 1,2
 
Acute worsening of dystonia in children is very distressful, painful and can progress to a life-
threatening episode of status dystonicus, most typically in adolescents with cerebral palsy, with a 
10% mortality and a need for prolonged hospital admission. 
3
 
Status dystonicus may occur spontaneously or be triggered by several factors, such as infection, gut 
dysmotilty, abrupt medication withdrawal, or disruption of Deep Brain Stimulation (DBS).
4 
Some 
chldren are prone to recurrent episodes. 
5
 
 The evidence-base for pharmacological management of acute dystonia is limited. Typical 
management strategies involve the administration of high dose benzodiazepines and opiates which 
can result in respiratory depression and necessitate admission to a Paediatric Intensive Care Unit 
(PICU). 
6
 
Clonidine 
Clonidine is an α-2 receptor agonist and imidazoline receptor agonist. Clonidine is a centrally active 
antihypertensive agent, with a short half-life, and effective in the treatment of mild, moderate and 
severe hypertension, alone or in combination with other drugs.
7
  
Use of clonidine has been previously reported in the older literature as useful in the acute 
management of neuroleptic-induced tardive dyskinesia in adults being managed for psychosis using 
doses of about 500 micrograms (mcg) per day
8
. Clonidine has also been found to be useful in the 
management of alcohol, opiate, and nicotine withdrawal syndromes and tic disorders in large 
randomized controlled studies using clonidine patches
9
 and also tics with co-existing attention-
deficit/hyperactivity disorder (ADHD).
10
 Additionally clonidine has mild sedative effects, which is 
advantageous in the management of sleep disorders, especially in children with 
neurodevelopmental disorders
11 
and more recently clonidine was reported as highly beneficial in the 
mangement of acute NMDA-receptor antibody-meditated encephalitis for the movement and 
neuropsychiatric symptoms
12
 
Our experience with out-patient use of clonidine for the chronic management of childhood dystonia 
in the out-patient setting has recently been reported (Sayer EJPN epub 2017)
13
 as a result of which 
we no longer perform an in-hospital test-dose procedure of 1microgram/kg of oral clonidine 
followed by blood pressure measurement to exclude hypotension because no cases of hypotension 
were provoked. 
Clonidine can be very beneficial in the management of acute worsening of dystonia as well as in 
established status dystonicus, although the exact mechanisms for these actions are not known, 
hypnotic and anxiolytic actions probably play and important role .  
In comparison to benzodiazepines and opiates, clonidine is a less sedating alternative which causes 
little or no respiratory depression and can obviate the need for subsequent ventilator support.
6
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Clonidine can be administered via enteral, continuous intravenous (IV) infusion, and transdermal 
slow release routes
9
. 
There is little experience of use of iv clonidine outside the PICU setting and no reports of clonidine 
for acute dystonia in childhood.  
Here we report the use of high dose clonidine in the management of severe acute dystonia outside 
PICU in a case-series of 5 children. Importantly with one exception, ventilatory support was not 
required. We also report our experience with transdermal clonidine which reduces reliance on iv 
administration in the context of unreliable gut function. 
Methods 
The management of 5 children (3 female, age range 8-14 years) suffering from an acute 
exacerbation of secondary dystonia requiring hospital admission under the care of the Paediatric 
Complex Movement Disorder Service at the Evelina London Children’s Hospital was retrospectively 
and prospectively reviewed. 
Dystonia severity was measured, using the Dystonia Severity Assessment Plan (DSAP) grades 1-5.
14
 
Grades 1-5 defined as:  
Grade 1 : Sitting comfortably 
Grade 2: Unable to sit but able to sleep at night 
Grade 3: Unable to sleep or sit comfortably 
Grade 4: Metabolic decompensation, sweating, rhabdomyolysis,requires HDU 
Grade 5: Status dystonicus & multi-organ failure, requires PICU 
The DSAP grading (see table 1 for details) has recently been used to describe approaches to the 
management of status dystonicus
15
 can also be.re-phrased as ‘Dystonia Soon As Possible’ to 
emphasize the underlying urgency to control dystonia and prevent inevitable progression to DSAP 
grades 4 and 5. 
The daily dose of clonidine (in mcg/kg/hr) and route of administration were recorded for each day of 
hospital admission. Co-administration of any other medical treatments for dystonia and their route 
of administration were also recorded. Cardiovascular and respiratory clinical status were reviewed 
by recording the daily mean and maximum Paediatric Early Warning Scores (PEWS). 
Results 
The five cases are briefly presented. 
Case1:  A nine year old boy with dystonic cerebral palsy, one of twins , with Gross Motor Function 
Classification System (GMFCS)
16
 level 5 and Manual Abilities Classification System (MACS)
 16
 level 5 
Communication Function Classification System (CFCS)
 16
 level V secondary to prematurity at 24 
weeks gestation associated with haemorrhagic destruction of cerebellar hemispheres, sensorineural 
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deafness, developmental delay, learning difficulties, renal calculi and sleep problems. Feeding was 
via gastrostomy though he usually managed some oral feeds. He had been successfully managed for 
four years with bilateral globus pallidus internus (GPI) deep brain stimulation followed by unilateral 
cochlear implantation at 5years of age (see Lin et al EJPN special edition 2016)
17
. He presented 
acutely with status dystonicus and rhabdomyolisis, DSAP level V, figure 1a, 10 days after Deep Brain 
Stimulation removal in November 2012 because of neurostimulator erosion associated with infra-
clavicular neurostimulator pocket infection requiring high dose antibiotics. High dose IV clonidine, up 
to 9mcg/kg/hour, as high-dose benzodiazepines (midazolam, lorazepam, diazepam, and nitrazepam), 
propofol and morphine infusions were ineffective. Figure 1b shows optimization of the clonidine up 
to a brief maximum of 9micrograms/kg/hr which was rapidly weaned after re-implantation of the 
DBS system. Note the rise in the PEWS score in the first 3 weeks during the midazolam infusion. 
Despite the clonidine dose rising after initial DBS re-implantation, the PEWS is more stable than 
when on midazolam. The transdermal clonidine is introduced on day 48 because of ileus and several 
episodes of unexplained gastric mucosal bleeding for which no cause was found on endoscopy, 
building up to a steady transdermal dose of 2mcg/kg/hr of clonindine. Figure 1b shows the slow 
improvement in the DSAP score which demonstrates sitting consistently comfortably at 240-250days 
after initial admission. He was successfully discharged home 9 months after and remains on 
900micrograms of transdermal clonidine in the form of 3 three-hundred microgram patches 4 years 
later: each patch lasting 7 days. 
Case2:  
An eleven year old girl with Pantothenate Kinases Associated Neurodegeneration (PKAN) with a 
positive PANK2-mutation presenting with severe sustained generalized dystonia, GMFCS level V, 
feeding via gastrostomy, was transferred for further management from another tertiary referral 
centre due to acute worsening  dystonia. On admission, sleep and sitting out in a chair were severely 
disrupted (DSAP grade 3). Gradual escalation of clonidine up to 2.1mcg/kg/hr over 18 days was 
administered enterally for dystonia control (figure 2). Sleep improved by day 20 (DSAP Grade 2) and 
intermittent sitting out in her chair from day 16 (DSAP Grade 1). Deep Brain Stimulation was 
implanted as planned 3 months later.  
Case3: 
A seven year old girl with microcephaly, severe choreoathetoid movement disorder and profound 
developmental delay with no underlying diagnosis and GMFCS level V was admitted after Deep Brain 
stimulation surgery with severe hyperkinetic movements, worsening during an intercurrent 
respiratory infection. Escalation of oral clonidine up to 3.9mcg/kg/hour on day 15 resulted in a DSAP 
improvement from Grade 3 (unable to sleep) to DSAP Grade 1 on day 17 and also allowed weaning 
of nitrazepam and reduced the involuntary movements during the episode of infection. (figure 3) 
Case4: 
A fourteen year-old girl with early epileptic encephalopathy and choreoathetoid movement 
disorder, associated with GNAO1 mutation, GMFCS level IV presented to her local hospital with a 
severe dystonic-choreoatheoid crisis requiring admission to her Regional Paediatric Intensive Care 
Unit (PICU) for 5 weeks from which she was transferred to our unit for deep brain stimulation (DBS). 
Prior to transfer, management of the dystonic-choreoathethoid crisis was greatly helped by initiating 
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a high-dose clonidine IV infusion at 3.5micrograms/kg/hour. This was subsequently converted to  
enteral clonidine via nasogastric tube infusion. This clonidine infusion allowed comfortable lying in 
bed and sleeping at night but sitting out in her chair only resumed after bilateral globus pallidus 
internus (GPi) DBS followed by gradual mobilisation leading to gradual clonidine weaning to zero 
prior to transfer back to her local hospital (figure 4). 
Case5:  
A fourteen year old boy with dystonic-dyskinetic cerebral palsy and epilepsy, GMFCS Level V, severe 
sleep problems and jejunostomy feeding, presented in status dystonicus in July 2015, associated 
with septicaemia and ileus, after having bilateral hip surgery, requiring admission to PICU.  
He was started on IV clonidine, which helped his symptoms to settle gradually.  
There was a noticeable exacerbation of his dystonia during his treatment course, with increasing of 
DSAP score from 1 to 3, when the dose of clonidine was inadvertently reduced from 1mcg/kg/hour 
to 0.1mcg/kg/hour, followed by a quick response and clinical improvement once he was given  the 
correct dose (figure 5). 
The clonidine infusion reached a maximum rate of 2.7mcg/kg/hr and  was switched to enteral 
administration, when gut mobility was restored (figure 5). 
Relationship of PEWS, DSAP and Clonidine doses 
A major clinical concern is the possibility of cardiovascular compromise relating to bradycardia and 
hypotension with clonidine use. Although a relative bradycardia during sleep was an almost 
invariable finding, the heart rate always increased with appropriate physiological variability during 
arousal or wakeful hours . The Paediatric Early Warning Score is designed to give nursing and 
medical teams early indication of deteriorating vital signs and possible need for escalation of life 
support (reference). In all 5 cases the PEWS varied with the underlying illness of the child but did not 
worsen with increasing doses of clonidine. In cases 2,3 and 5 the PEWS severity matched DSAP 
severity and improved as the clonidine increased. This is particularly seen in cases 3 and 5. In case 3, 
an intercurrent viral infection from day 9 to 13 resulted in worsening of the PEWS score to 4.5. The 
clonidine was then further increased over day 13-15 and the DSAP Grade 3 dropped to between 
down to Grade 1-2 on day 17.   In case 5 an administrative error resulted in only 0.1mcg/kg/hr being 
administered instead of 1.0mcg/kg/hr leading to immediate rebound dystonia reflected in a high 
DSAP grade 3 and a PEWS of 3.5 which improved as soon as the correct infusion dose  of 
1.0mcg/kg/hr was restored.  
Overall there was no significant correlation between worsening PEWS and clonidine dose 
(Spearman’s rho 0.0494; p=0.7928) and no episodes of clinically significant hypotension, though as 
anticipated nursing staff did alert medical teams when bradycardia was recorded almost always 
during sleep and generally abolished by wakefulness. 
Discussion 
We present this illustrative case-series of 5 children, including 2 cases of cerebral palsy with acute 
status dystonicus refractory to conventional drug management. Clonidine was administered via 
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enteral, intravenous, and transdermal routes at a median dose of 2.5mcg/kg/hr (range 0.1 to 9 
mcg/kg/hr) with benefit in reducing dystonia, restoring sleep and allowing a return to sitting 
comfortably.  
An enteral dosage of 1-5mcg/Kg/dose may be administered initially 8-hourly  but if dystonia  breaks 
through , this dose may need to be administered more frequently.  In acute worsening dystonia in 
the hospital setting, typical doses of  0.5- 3mcg/kg/hour are usually very effective but we have had 
to use much higher doses  up to 9mcg/kg/hour if necessary, and in our experience does not result in 
hypotension or respiratory depression.  Clonidine can also be administered by continuous enteral 
infusion via NG tube or gastrostomy, by calculating the total daily dose and dividing by 24 hours to 
deliver. 
Intravenous clonidine dosage:  
Clonidine can be administered as IV Continuous infusion when enteral route is unsuitable owing to 
diarrhoea and vomiting, gut failure, or temporary loss of gastrostomy. Doses of 0.25-2.0 
mcg/kg/hour are mainly used in daily PICU practise, but for severe dystonia, consideration of higher 
doses as tolerated may be required. 
Transdermal slow release routes 
Transdermal patches are another option of administering clonidine, especially in patients with gut 
failure and the need to establishlong-term high dose of clonidine while avoiding the intravenous 
route of administration. This has recently been reported in a teenage boy with an end-stage 
leucodystrophy and severe dystonia receiving palliative care
18
. 
Administration of high dose clonidine was associated with avoiding the use of respiratory depressant 
benzodiazepines, morphine, and propofol thus avoiding invasive respiratory support for 4/5 cases 
during admission. 
The DSAP grade and clonidine in dystonia 
In all cases the DSAP grade
14,15
 improved or did not deteriorate as clonidine was increased. The DSAP 
helps to measure the important clinical variables of well-being in dystonic children: the ability to 
sleep and sit comfortably as well as monitor dystonia worsening: sweating, dehydration, 
rhabdomyolysis (DSAP Grade 4) and Status Dystonicus (DSAP Grade 5) associated with multi-organ 
failure. The DSAP also monitors the gradual recovery from status dystonicus and allows parents and 
healthcare professionals to determine progress. Children may still experience difficult dystonic 
episodes but the quality of life is greatly enhanced if the child is able to sleep 6 or more hours a day 
and to sit out in a chair for 1-2 hours a day. The sleep-wake pattern can be usefully monitored during 
exacerbations and indeed during dystonic crises using a simple 24-hour sleep-wake chart that 
monitors  sleep, wakefulness, comfort, dystonia and sitting out in a chair for each hour. This diary 
can be used as children are transferred to other units and at home and school. 
Clonidine and PEWS 
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Clonidine doses via all routes of administration did not correlate with a worsening PEWS score 
suggesting no additional compromise of cardiovascular or respiratory function at even very high 
doses.  
Clonidine and sleep bradycardia 
A universal observation of children with dystonia who are on clonidine is the relative bradycardia 
during sleep. This phenomenon is not observed in the awake state, indicating the physiological 
nature of the bradycardia during sleep. Such a bradycardia is not an indication for with-holding 
clonidine provided gentle stimulation of the child results in in a rise in heart rate to demonstrate an 
arousal-dependent variability in heart rate. 
Reducing un-necessary polypharmacy 
However where possible, all unsuccessful antidystonic medication should be discontinued by gradual 
weaning to avoid polypharmacy and the risk of gut ileus. 
 
Specific comment on side effects experienced on clondine 
Limitations of our report. 
These case histories merely illustrate that the condition of severe dystonia is often difficult to 
manage and often require coordinated multidisciplinary collaboration. Safely relieving acute severe 
dystonia without inducing respiratory failure and minimising invasive methods of administration has 
been our chief goal, but this report is nevertheless limited by the small number of cases. Over 
several years, our dosage regimens have become bolder as we have come to accept that higher total 
daily doses of clonidine are required in the severely dystonic child while recognising that tapering 
these doses or adjusting them to achieve the best night-day or sleep-wake pattern requires active 
clinical judgement. 
This work represents a parallel audit of clonidine use for dystonia in the out-patient clinic setting 
when smaller, and more slowly adjusted clonidine increments are made
13
. 
Contact from colleagues within the UK and abroad suggested that a descriptive account of some 
representative cases was needed to establish how we use clonidine effectively and safely, rather 
than the word-of-mouth jungle telegraph approach to date. 
It would be an extension to these initial case-history descriptions to collect more data with a wider 
clinical spectrum of cases on the precipitating factors leading to severe dystonia and status 
dystonicus and how to manage this effectively, preferably by early recognition and institution of a 
prophylactic plan. This has occurred informally in collaboration with our orthopaedic colleagues, 
anticipating worsening dystonia following planned surgery to hips and spine by instituting clonidine 
on admission for such surgery and early escalation as indicated postoperatively.  
It is anticipated that new tools such as a parent/carer-held ‘My Dystonia-Child’ APP, based on the 
DSAP and other measures, could help to monitor the well-being of children with dystonia and 
provide us with a larger database that could help gather information on all forms of management, 
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including medication, and life events of children with dystonia. Opening this process to a wider 
clinical group could help to both highlight the plight and refine the management of dystonia this 
difficult clinical group. 
 
Conclusion 
Acute worsening dystonia is a clinical emergency, requiring prompt and proper management.  The 
use of the dystonia severity action plan (DSAP) can help to recognise early signs of worsening 
dystonia and lead to intervention before status dystonicus is established. 
Management of acute worsening dystonia is extremely challenging, with the most commonly used 
short-term management strategies of using benzodiazepines and opiates associated with a 
significant risk of severe respiratory depression. 
High dose clonidine can be administered via IV or transdermal routes when ileus / gut-failure 
precludes the enteral route for the acute management of severe exacerbations of dystonia. 
Clonidine use in our small case-series was not associated with significant cardio-respiratory 
depression even at doses as high as 9 mcg/kg/hr but combination medication should be used with 
caution.  
The need for ‘emergency rescue medication for dystonia’ in any 24 hour period should prompt an 
upward adjustment of the total daily dose of clonidine in divided doses if possible or continuous 
administration by the most convenient route.  
Every route of administration has a drawback: waking the sleeping child to administer oral clonidine, 
the need to transfer to PICU or HDU for iv clonidine; the problems of administering clonidine when 
dealing with an ileus without intravenous access or infected iv lines that must be removed at night 
or at week-ends may be solved with transdermal clonidine. 
In our hospital transdermal patches were less expensive that the equivalent intravenous 
preparation, but the health economics of transdermal administration, by preventing healthcare cost 
escalation, may be a viable alternative for medium to long-term use as in case 1 who has been on 
transdermal clonidine for 4.0 years. 
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Figure 1. Case1: a. Nine-year old ex-25 week preterm twin boy in withdrawal status dystonicus (DSAP 
level 5 within 10 days after bilateral globus pallidus internus deep brain stimulation removal for 
battery-site erosion-infection. Enteral clonidine is replaced on day 6 by i.v. clonidine owing to a gut 
ileus. b. It takes 250 days for this child to consistently achieve comfortable sitting i.e. level 1 DSAP. Iv 
clonidine was eventually replaced by three 300microgramme/day transdermal clonidine patches on 
day 48, each of which have continued to the present time and the patches are changed every 7 days 
in rotation. For further details see text. 
Figure 2 An eleven year old girl with PANK2 disease and severe generalized dystonia, . Case 2 : 
GMCS level V, feeding via gastrostomy, was transferred from another tertiary referral centre due to 
acute worsening  dystonia. On admission, sleep and sitting out in a chair were severely disrupted 
(DSAP grade 3). Gradual escalation of clonidine up to 2.1mcg/kg/hr over 18 days was administered 
enterally for dystonia control. Sleep improved by day 20 (DSAP Grade 2) and intermittent sitting out 
in her chair from day 16 (DSAP Grade 1). Deep Brain Stimulation was implanted as planned 3 months 
later. 
Figure 3. Case 3: A seven year old girl with microcephaly, severe choreoathetoid movement disorder 
and profound developmental delay with no underlying diagnosis and GMFCS level V was admitted 
after Deep Brain stimulation surgery with severe hyperkinetic movements, worsening during an 
intercurrent respiratory infection. Escalation of oral clonidine up to 3.9mcg/kg/hour on day 15 
resulted in a DSAP improvement from Grade 3 (unable to sleep) to DSAP Grade 1 on day 17 and also 
allowed weaning of nitrazepam and reduced the involuntary movements during the episode of 
infection.  
Figure 4. Case 4: A fourteen year-old girl with early epileptic encephalopathy and choreoathetoid 
movement disorder, associated with GNAO1 mutation, GMFCS level IV presented to her local 
hospital with a severe dystonic-choreoatheoid crisis requiring admission to her Regional Paediatric 
Intensive Care Unit (PICU) for 5 weeks from which she was transferred to our unit for deep brain 
stimulation (DBS). Prior to transfer, management of the dystonic-choreoathethoid crisis was greatly 
helped by initiating a high-dose clonidine IV infusion at 3.5micrograms/kg/hour. This was 
subsequently converted to  enteral clonidine via nasogastric tube infusion. This clonidine infusion 
allowed comfortable lying in bed and sleeping at night but sitting out in her chair only resumed after 
bilateral globus pallidus internus (GPi) DBS followed by gradual mobilisation leading to gradual 
clonidine weaning to zero prior to transfer back to her local hospital. 
Figure 5. Case 5: A fourteen year old boy with dystonic-dyskinetic cerebral palsy and epilepsy, 
GMFCS Level V, severe sleep problems and jejunostomy feeding, presented in status dystonicus in 
July 2015, associated with septicaemia and ileus, after having bilateral hip surgery, requiring 
admission to PICU.  He was started on IV clonidine, which helped his symptoms to settle gradually. 
There was a noticeable exacerbation of his dystonia during his treatment course, with increasing of 
DSAP score from 1 to 3, when the dose of clonidine was inadvertently reduced from 1mcg/kg/hour 
to 0.1mcg/kg/hour, followed by a quick response and clinical improvement once he was given  the 
correct dose (figure 5). 
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Figure 1. Case1. Nine-year old ex-25 week preterm twin boy in withdrawal status 
dystonicus, DSAP level 5, within 10 days after bilateral globus pallidus internus deep 
brain stimulation removal for battery-site erosion-infection.  
Top: The Dystonia Severity Assessment Plan (DSAP).  It takes 250 days for this child to 
consistently achieve comfortable sitting i.e. level 1 DSAP. 
Bottom: Bilateral Globus Pallidus Internus Deep Brain Stimulation (DBS, grey rectangle) 
is re-introduced on day 17 after a course of i.v. antibiotics. Enteral clonidine is replaced 
on day 6 by i.v. clonidine owing to a gut ileus (lower figure) and enteral clonidien re-
introduced on day 25. I.v. clonidine was eventually replaced by three 
300microgramme/day transdermal clonidine patches on day 48, each of which have 
continued to the present time and the patches are changed every 7 days in rotation. For 
further details see text. 
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Figure 2.  
An eleven year old girl with PANK2 disease and severe generalized dystonia, Case 2 . 
GMCS level V, feeding via gastrostomy, was transferred from another tertiary referral 
centre due to acute worsening  dystonia. On admission, sleep and sitting out in a chair 
were severely disrupted (DSAP grade 3). Gradual escalation of clonidine up to 
2.1mcg/kg/hr over 18 days was administered enterally for dystonia control. Sleep 
improved by day 20 (DSAP Grade 2) and intermittent sitting out in her chair from day 
16 (DSAP Grade 1). Deep Brain Stimulation was implanted as planned 3 months later. 
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Figure 3. Case 3. A seven year old girl with microcephaly, severe choreoathetoid 
movement disorder and profound developmental delay with no underlying diagnosis 
and GMFCS level V was admitted after Deep Brain stimulation surgery with severe 
hyperkinetic movements, worsening during an intercurrent respiratory infection. 
Escalation of oral clonidine up to 3.9mcg/kg/hour on day 15 resulted in a DSAP 
improvement from Grade 3 (unable to sleep) to DSAP Grade 1 (sitting comfortably) on 
day 17 and also allowed weaning of nitrazepam and reduced the involuntary 
movements during the episode of infection.  
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Figure 4. Case 4. A fourteen year-old girl with early epileptic encephalopathy and 
choreoathetoid movement disorder, associated with GNAO1 mutation, GMFCS level IV 
presented to her local hospital with a severe dystonic-choreoatheoid crisis requiring 
admission to her Regional Paediatric Intensive Care Unit (PICU) for 5 weeks from which 
she was transferred to our unit for deep brain stimulation (DBS). Prior to transfer, 
management of the dystonic-choreoathethoid crisis was greatly helped by initiating a 
high-dose clonidine IV infusion at 3.5micrograms/kg/hour. This was subsequently 
converted to enteral clonidine via a nasogastric tube infusion. This clonidine infusion 
allowed comfortable lying in bed and sleeping at night (DSAP grade 2) but sitting out in 
her chair (DSAP grade 1) only resumed after bilateral globus pallidus internus (GPi) DBS 
followed by gradual mobilisation leading to gradual clonidine weaning to zero prior to 
transfer back to her local hospital. 
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Figure 5. Case 5. A fourteen year old boy with dystonic-dyskinetic cerebral palsy and 
epilepsy, GMFCS Level V, severe sleep problems and jejunostomy feeding, presented in 
sub-status dystonicus, unable to sleep or sit (DSAP grade 3) in July 2015, associated 
with septicaemia and ileus, after having bilateral hip surgery, requiring admission to 
PICU.  He was started on IV clonidine, which helped his symptoms to settle gradually. 
There was a noticeable exacerbation of his dystonia during his treatment course, with 
increasing of DSAP score from 1 to 3, when the dose of clonidine was inadvertently 
reduced from 1mcg/kg/hour to 0.1mcg/kg/hour, followed by a quick improvement in 
the DSAP score from level 3 to level 1and clinical improvement once the correct i.v. 
clonidine infusion dose was admiistered. 
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Status dystonicus remains a complex multisystem disorder and usually involves a 
multidisciplinary approach. 
Clonidine may provide a suitable alternative to benzodiazepines and opiate infusions in the 
management of childhood status dystonicus. 
Clonidine doses of 0.5-3mcg/kg/hour (range 0.1- 9mcg/kg/hour) may be necessary to 
safely manage acute severe dystonia and in our experience does not result in severe 
hypotension or respiratory depression 
Severe dystonia is effectively managed using the Dystonia Severity Assessment Plan 
(DSAP) scoring system which monitors worsening and improvement in dystonia based 
on meaningful function and comfort 
Clonidine helps to restore sleep in dystonic children which in turn is crucial for breaking 
the vicious cycle of continuous muscular contraction of dystonia 
Attention to the sleep patterns of children with dystonia and improving their often 
fragmented sleep forms the cornerstone of dystonia management 
 
 
